Last edition
News about "Datroway"
EMA Recommends Approval of Datroway for First-Line Treatment of Triple-Negative Breast Cancer
AstraZeneca and Daiichi Sankyo have received a positive recommendation from the European Medicines Agency's CHMP for Datroway as a first-line treatment for unresectable or metastatic triple-negative breast cancer in patients who are not eligible for immunotherapy, supported by Phase 3 trial results demonstrating improved survival and disease control.
Datroway | 29/06/2026 | By News Bureau
Daiichi Sankyo Unveils 5-Year Oncology Growth Strategy
Daiichi Sankyo launches a 5-year strategy targeting global oncology leadership, aiming for 2.3 trillion yen in oncology revenue by 2030 through new indications, breakthrough technologies, and expanded commercialisation capabilities.
Datroway | 12/05/2026 | By News Bureau | 172
First Patient Dosed in Phase III Tropian-Lung17 Trial of Datroway in Advanced NSCLC
The global Phase III study evaluates Datroway versus docetaxel in Trop2 NMR-positive advanced nonsquamous NSCLC patients previously treated with immunotherapy and platinum chemotherapy.
Datroway | 14/01/2026 | By News Bureau | 216
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy